Welcome to our dedicated page for Alterity Therapeutics American Depositary Shares news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics American Depositary Shares stock.
Alterity Therapeutics Limited (symbol: ATHE) is a pioneering biopharmaceutical company based in Melbourne, Australia, focused on developing therapeutic drugs for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and multiple system atrophy. Founded in 1997 and originally known as Prana Biotechnology Limited, the company rebranded to Alterity Therapeutics Limited in April 2019.
The company’s flagship drug candidate, ATH434, has successfully completed Phase I clinical trials and is geared towards treating Parkinson's disease and other associated movement disorders. The drug has shown promise in clinical evaluations to slow disease progression, thus improving the quality of life for patients.
Alterity is also advancing PBT2, another leading drug candidate, originally designed as an antimicrobial agent but repurposed for treating Alzheimer's and Huntington's diseases. PBT2 has garnered attention owing to its potential to tackle the cognitive decline associated with these debilitating conditions.
Alterity Therapeutics is actively engaged in multiple research collaborations and partnerships with academic institutions and pharmaceutical companies to enhance its drug development pipeline. Their multi-faceted approach to addressing neurodegenerative disorders underscores the company's commitment to innovation and patient care.
Recent achievements include a collaborative study titled “A multimodal approach for diagnosis of early Multiple System Atrophy,” presented at the MDS 2023 conference, demonstrating the company's dedication to advancing scientific understanding and treatment methodologies.
Financially, Alterity Therapeutics maintains a stable condition, actively investing in research and development to push forward its clinical programs. The company's strategic initiatives and ongoing projects highlight its pivotal role in the healthcare domain, with a focus on creating significant therapeutic advancements.
For investors and stakeholders, Alterity Therapeutics represents a compelling opportunity in the biopharmaceutical sector, with a clear focus on addressing unmet medical needs through innovative drug discovery and development.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced an expansion of the Phase 2 clinical trial for ATH434 targeting Multiple System Atrophy (MSA), a rare neurodegenerative disorder. The double-blind, placebo-controlled study will assess ATH434's effects on biomarkers related to α-synuclein aggregation and iron levels over 12 months across 30 sites in Australia, New Zealand, Europe, and the U.S. Additionally, the bioMUSE study will expand to 20 patients, enhancing data for the trial. ATH434 has Orphan designation and aims to improve the quality of life for MSA patients.
Alterity Therapeutics (NASDAQ: ATHE) reported progress in its biomarker study, bioMUSE, for early Multiple System Atrophy (MSA) patients. Data presented at the International Parkinson and Movement Disorder Society Congress 2021 highlighted the identification of iron accumulation in the brain as a potential biomarker for MSA. This could enhance patient selection for the upcoming Phase 2 trial of ATH434, aimed at treating MSA. The ongoing study is vital for understanding disease progression in MSA, which currently has no approved therapies.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced a Notice of Allowance from the USPTO for its patent application No. 17/239,375, securing exclusivity for a new group of iron chaperones aimed at addressing neurodegenerative diseases like Alzheimer's and Parkinson's. This patent covers over 80 novel compounds and follows the recent grant of another patent for 150 additional compounds. The company plans to advance its lead clinical asset, ATH434, into a Phase 2 trial, targeting Multiple System Atrophy and other conditions, while benefiting from approximately 20 years of patent exclusivity.
Alterity Therapeutics reported positive guidance from the European Medicines Agency for its ATH434 Phase 2 clinical trial in treating Multiple System Atrophy (MSA). During Q4 FY21, the company ended with a cash balance of A$28M, bolstered by $17M proceeds from an equity facility. An independent study published in Movement Disorders confirmed ATH434's neuroprotective effects in MSA models. The company aims to commence its clinical trial by year-end 2021, following progress in its natural history study underway at Vanderbilt University.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced study results showing that ATH434 can reduce α–synuclein related neurodegeneration in a murine model of Multiple System Atrophy (MSA). Published in Movement Disorders, the study found that ATH434 preserves neurons and enhances motor functions. The company plans to initiate a Phase 2 clinical trial by year-end. MSA, affecting about 15,000 patients in the U.S., currently has no approved therapy, making ATH434 a potential breakthrough treatment.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the granting of a new composition of matter patent from the USPTO, covering a class of iron chaperones aimed at redistributing excess iron in the central nervous system. This patent secures a monopoly over 150 pharmaceutical compositions targeting neurodegenerative diseases such as Alzheimer's and Parkinson's. The company plans to launch a Phase 2 trial for its lead candidate, ATH434, by year-end, which is developed for Multiple System Atrophy (MSA) and is expected to advance their drug development efforts.
Alterity Therapeutics has received positive guidance from the European Medicines Agency (EMA) for its Phase 2 clinical trial of ATH434 targeting Multiple System Atrophy (MSA). The EMA supports recruiting early-stage MSA patients and the use of biomarkers to identify them. Alterity aims to utilize the EMA's feedback to improve trial design, aiming to generate robust data for regulatory authorities. The trial is set to launch in the second half of the year, focusing on a disease modifying approach as no approved treatment currently exists for MSA.
Alterity Therapeutics Limited (NASDAQ: ATHE) reported a cash balance of $32.8M for Q3 FY21, with operational cash outflows of $5M. The company received a $495K grant from the Michael J. Fox Foundation for Parkinson's disease research related to its lead drug candidate, ATH434. Progress continues on the Phase 2 trial for ATH434, with 80% of the target population recruited in a related study at Vanderbilt University. Dr David Stamler was appointed CEO, succeeding Geoffrey Kempler.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced an oral presentation at the American Academy of Neurology conference on April 21, 2021, regarding its lead compound ATH434, aimed at treating Parkinsonian disorders. The presentation showed that ATH434 is neuroprotective, preserving neurons in critical brain regions and improving motor function in an animal model of Multiple System Atrophy (MSA). The findings provide further evidence of ATH434's potential as a disease-modifying treatment, supported by data showing reductions in toxic α-synuclein levels and improved coordination.
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) will present at the 7th International Congress of Multiple System Atrophy (MSA2021) on February 26-27, 2021. This premier virtual event focuses on MSA, a severe neurodegenerative disease without an approved treatment. Alterity will showcase data on ATH434, its lead candidate, highlighting its safety profile concerning blood pressure regulation—a critical factor in MSA. The company is also conducting a natural history study in partnership with Vanderbilt University to support future treatment studies.
FAQ
What is the current stock price of Alterity Therapeutics American Depositary Shares (ATHE)?
What is the market cap of Alterity Therapeutics American Depositary Shares (ATHE)?
What does Alterity Therapeutics Limited specialize in?
What are the company's lead drug candidates?
Where is Alterity Therapeutics Limited based?
What was Alterity Therapeutics formerly known as?
What recent achievements has the company made?
Who is the CEO of Alterity Therapeutics Limited?
What is the financial condition of Alterity Therapeutics?
What does ATH434 target?
What does PBT2 target?
What type of collaborations is Alterity Therapeutics engaged in?
